免疫組織化学（IHC）市場：製品、用途、エンドユーザー、地域別、2026～2032年

免疫組織化学（IHC）市場の評価-2026～2032年

世界のがん患者の増加が免疫組織化学（IHC）の採用を促進しています。IHC技術の革新は感度と特異性を高め、より多くの研究者や臨床医を惹きつけており、市場規模は2024年に20億6,000万米ドルを突破し、2032年には約33億7,000万米ドルに達します。

これに加えて、がん研究に対する政府の有利な規制や資金援助が免疫組織化学（IHC）の採用に拍車をかけています。テーラーメード治療へのシフトは、IHCによって同定される正確なバイオマーカーの必要性を高めており、これによって市場は2026～2032年までCAGR 6.37％で成長します。

免疫組織化学（IHC）市場：定義/概要

免疫組織化学（IHC）は、抗体ベースの染色を用いて組織切片中の特定タンパク質の存在と位置を可視化するために用いられる実験技術です。この方法は、標的抗原に結合する抗体の特異性を利用して、研究者や臨床医が細胞構造を同定し、組織の病理学的変化を理解することを可能にします。通常、組織は固定され、切片化され、検出可能なマーカーと結合した抗体で処理され、顕微鏡下での可視化が可能となります。

IHCは臨床診断と調査の両方で広く利用されています。病理学では、腫瘍マーカーや細胞分化を同定することにより、がんを含む様々な疾患の診断に重要な役割を果たしています。さらに、IHCは基礎研究において、タンパク質の発現パターン、細胞の局在、特定の細胞経路に対する治療の効果を研究するために使用されます。タンパク質発現に空間的背景を与えるその能力は、疾患メカニズムや組織アーキテクチャを理解する上で非常に貴重です。

VMRの中身

産業レポートの中身

当社のレポートには、実用的なデータと将来を見据えた分析が含まれており、ピッチの作成、ビジネスプランの作成、プレゼンテーションの構築、提案書の作成に役立ちます。

個別化医療セグメントにおける研究開発活動の高まりは、免疫組織化学（IHC）の採用をどのように増加させるでしょうか？

世界のがんの有病率の増加は免疫組織化学（IHC）市場の重要な促進要因です。世界保健機関（WHO）によると、がんは2020年に約1,000万人の死亡の原因となり、乳がん、肺がん、結腸がん、前立腺がんが最も多いタイプです。IHCは、がんの診断、予後、治療計画において重要な役割を担っており、こうした技術に対する需要の高まりにつながっています。マルチプレックスIHCやデジタルパソロジーのような最近のIHC技術の進歩は、腫瘍学におけるIHCの有用性をさらに高めています。2024年3月、ロシュはがん診断におけるワークフローの効率と精度の向上を目指した新しい自動化IHCプラットフォームの発売を発表しました。

個別化医療セグメントにおける研究開発の活発化が、IHC市場を前進させています。米国国立衛生ラボ（NIH）は、2023会計年度に4億1,900万米ドルを精密医療研究に割り当てると報告しています。IHC技術は、特定のバイオマーカーや分子標的を同定し、個々の患者に合わせた治療戦略を可能にするために不可欠です。この動向は、自己免疫疾患や神経変性疾患を含む様々な疾患に対する標的療法の開発において特に顕著です。

新興経済国でのIHC採用の増加が市場成長の原動力となっています。インド医療研究評議会（ICMR）は、2019～2023年にかけて公立病院全体でIHC検査量が年間15%増加すると報告しています。この動向の要因としては、ヘルスケアインフラの改善、先進的診断技術に対する意識の高まり、これらの地域における医療費の増加などが挙げられます。多くの新興諸国で流行している感染症の診断におけるIHCの汎用性が、その採用をさらに後押ししています。

異なるプラットフォームや機関間での標準化の問題は市場成長の妨げになるか？

異なるプラットフォームや施設間での標準化の問題は、IHCの状況をさらに複雑にしています。サンプル調製、染色プロトコール、解釈基準にばらつきがあると、結果に食い違いが生じる可能性があります。このような標準化の欠如は、特に一貫したデータが不可欠な多施設研究や臨床検査において、IHC所見の信頼性を損なう可能性があります。

また、分子技術や次世代シーケンスなどの代替技術の出現は、IHC市場に競争圧力をもたらしています。これらの代替技術がより進歩し、利用しやすくなるにつれ、タンパク質分析や疾患の特徴付けにおいて、より信頼性の高い、あるいは費用対効果の高いソリューションを提供する可能性があります。この動向は、研究者や臨床医が診断や研究のニーズに対して新たな方法を模索する中で、IHCの成長や応用を制限する可能性があります。

さらに、規制状況はIHC市場に課題を投げかけています。新しい抗体や診断キットの承認プロセスは長く複雑なため、革新的な製品の導入が遅れる可能性があります。また、厳しい規制によって特定の試薬の入手が制限されることもあり、市場力学に影響を与え、このセグメントへの参入を目指す中小企業にとって障壁となっています。

目次

第1章 世界の免疫組織化学（IHC）市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の免疫組織化学（IHC）市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 免疫組織化学（IHC）の世界市場：製品別

• 概要
• 抗体
• 試薬
• 機器
• キット

第6章 免疫組織化学（IHC）の世界市場：用途別

• 概要
• 診断
• 研究
• 法医学

第7章 免疫組織化学（IHC）の世界市場：エンドユーザー別

• 概要
• 病院・診断ラボ
• 学術・研究機関
• その他

第8章 免疫組織化学（IHC）の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の免疫組織化学（IHC）市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• F. Agilent Technologies
• Roche Diagnostics
• Thermo Fisher Scientific
• Merck KGaA
• Abcam plc
• Bio-Rad Laboratories
• PerkinElmer, Inc.
• Dako（part of Agilent）
• Leica Biosystems
• Cell Signaling Technology
• F. Sigma-Aldrich（Merck）
• Miltenyi BIoTec
• Genetex, Inc.
• Ventana Medical Systems（Roche）
• Fujifilm
• Biocare Medical
• Santa Cruz BIoTechnology
• Zymed Laboratories（Thermo Fisher）
• NeoGenomics Laboratories
• Enzo Life Sciences

第11章 企業プロファイル付録

• 関連調査

Immunohistochemistry (IHC) Market Valuation - 2026-2032

Increasing cancer cases globally is propelling the adoption of immunohistochemistry (IHC). Innovations in IHC techniques enhance sensitivity and specificity, attracting more researchers and clinicians is driving the market size surpass USD 2.06 Billion valued in 2024 to reach a valuation of around USD 3.37 Billion by 2032.

In addition to this, favorable government regulations and funding for cancer research is spurring up the adoption of immunohistochemistry (IHC). The shift towards tailored therapies boosts the need for precise biomarkers identified through IHC, this is enabling the market grow at a CAGR of 6.37% from 2026 to 2032.

Immunohistochemistry (IHC) Market: Definition/ Overview

Immunohistochemistry (IHC) is a laboratory technique used to visualize the presence and location of specific proteins in tissue sections using antibody-based staining. This method leverages the specificity of antibodies to bind to target antigens, allowing researchers and clinicians to identify cellular structures and understand pathological changes in tissues. Typically, tissues are fixed, sectioned, and treated with antibodies that are linked to a detectable marker, enabling visualization under a microscope.

IHC is widely utilized in both clinical diagnostics and research. In pathology, it plays a crucial role in diagnosing various diseases, including cancers, by identifying tumor markers and cellular differentiation. Additionally, IHC is used in basic research to study protein expression patterns, cellular localization, and the effects of treatments on specific cellular pathways. Its ability to provide spatial context to protein expression makes it invaluable in understanding disease mechanisms and tissue architecture.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Rising Research and Development Activities in the Field of Personalized Medicine Increasing Adoption of Immunohistochemistry (IHC)?

The growing prevalence of cancer worldwide is a significant driver of the Immunohistochemistry (IHC) market. According to the World Health Organization, cancer was responsible for nearly 10 million deaths in 2020, with breast, lung, colon, and prostate cancers being the most common types. IHC plays a crucial role in cancer diagnosis, prognosis, and treatment planning, leading to increased demand for these techniques. Recent advancements in IHC technologies, such as multiplex IHC and digital pathology, have further enhanced its utility in oncology. In March 2024, Roche announced the launch of its new automated IHC platform, aiming to improve workflow efficiency and accuracy in cancer diagnostics.

Increasing research and development activities in the field of personalized medicine are propelling the IHC market forward. The U.S. National Institutes of Health (NIH) reported allocating $419 million for precision medicine research in the fiscal year 2023. IHC techniques are essential for identifying specific biomarkers and molecular targets, enabling tailored treatment strategies for individual patients. This trend is particularly evident in the development of targeted therapies for various diseases, including autoimmune disorders and neurodegenerative conditions.

The rising adoption of IHC in emerging economies is driving market growth. The Indian Council of Medical Research (ICMR) reported a 15% annual increase in IHC test volumes across public hospitals from 2019 to 2023. Factors contributing to this trend include improving healthcare infrastructure, increasing awareness about advanced diagnostic techniques, and growing healthcare expenditure in these regions. IHC's versatility in diagnosing infectious diseases, which are prevalent in many developing countries, further fuels its adoption.

Will Issues of Standardization across Different Platforms and Institutions Hindering the Market Growth?

The issue of standardization across different platforms and institutions further complicates the IHC landscape. Variability in sample preparation, staining protocols, and interpretation criteria can lead to discrepancies in results. This lack of standardization can undermine confidence in IHC findings, particularly in multicenter studies or clinical trials where consistent data is essential.

Also, the emergence of alternative technologies, such as molecular techniques and next-generation sequencing, presents competitive pressure on the IHC market. As these alternatives become more advanced and accessible, they may offer more reliable or cost-effective solutions for protein analysis and disease characterization. This trend could potentially limit the growth and application of IHC, as researchers and clinicians explore new methods for their diagnostic and research needs.

Additionally, the regulatory landscape poses challenges for the IHC market. The approval processes for new antibodies and diagnostic kits can be lengthy and complex, slowing down the introduction of innovative products. Stringent regulations can also limit the availability of certain reagents, affecting the market dynamics and creating barriers for smaller companies aiming to enter the field.

Category-Wise Acumens

Which Factors are Contributing Antibodies Segment Dominance in Immunohistochemistry (IHC) Market?

Antibodies are at the forefront of the Immunohistochemistry (IHC) market, playing a crucial role in detecting and visualizing specific antigens in tissue samples. Primary antibodies, in particular, are essential for precise target identification and are available in both monoclonal and polyclonal forms. According to the National Cancer Institute, over 80% of cancer diagnoses in the United States involved IHC techniques in 2023, highlighting the widespread use of antibodies in clinical settings. The continuous development of highly specific and sensitive antibodies has significantly improved the accuracy and reliability of IHC assays.

The demand for multiplex IHC antibodies is rapidly growing, driven by the need to analyze multiple biomarkers simultaneously in complex diseases like cancer. The U.S. Food and Drug Administration (FDA) approved 14 companion diagnostic IHC tests between 2020 and 2023, many of which utilize multiplex antibody panels. This trend reflects the increasing importance of comprehensive molecular profiling in personalized medicine. Multiplex IHC allows researchers and clinicians to gain deeper insights into cellular interactions and disease mechanisms, leading to more informed treatment decisions.

Which Factors Enhance the Use of Immunohistochemistry (IHC) for Diagnostics?

Diagnostics continue to dominate the Immunohistochemistry (IHC) market, with cancer diagnosis being a primary application. IHC techniques are crucial for identifying specific biomarkers, determining tumor origin, and guiding treatment decisions in oncology. According to the National Cancer Institute, approximately 1.9 million new cancer cases were diagnosed in the United States in 2023, emphasizing the ongoing need for accurate diagnostic tools. The ability of IHC to provide detailed information about protein expression and cellular localization makes it indispensable in modern pathology laboratories.

IHC diagnostics are increasingly being utilized in the field of infectious diseases, particularly for identifying pathogens that are difficult to culture or detect through other methods. The Centers for Disease Control and Prevention (CDC) reported that IHC was used in 15% of challenging infectious disease cases in 2023, up from 10% in 2020. This trend has been accelerated by recent global health events, highlighting the need for rapid and accurate diagnostic techniques. IHC's ability to detect viral antigens in tissue samples has proven especially valuable in diagnosing and studying emerging infectious diseases.

Country/Region-wise Acumens

Will Presence of Major IHC Market Players in North America Driving Immunohistochemistry (IHC) Market Growth?

North America maintains its dominant position in the immunohistochemistry (IHC) market, driven by advanced healthcare infrastructure and high adoption rates of cutting-edge diagnostic technologies. The region's leadership is bolstered by substantial investment in research and development, particularly in the fields of oncology and personalized medicine. According to the National Cancer Institute, cancer research funding in the United States reached $7.1 billion in fiscal year 2023, highlighting the country's commitment to advancing diagnostic and treatment capabilities. This investment directly translates to increased demand for sophisticated IHC techniques and products. In January 2024, Roche Diagnostics unveiled its next-generation IHC platform in the U.S. market, featuring enhanced automation and improved staining consistency for more accurate diagnoses.

The presence of major IHC market players and a robust regulatory framework contribute significantly to North America's market dominance. The U.S. Food and Drug Administration (FDA) approved 28 IHC-based companion diagnostic tests between 2020 and 2023, underscoring the region's leadership in translating research into clinical applications. These approvals facilitate the integration of IHC diagnostics into standard clinical practice, particularly in oncology. The region's large and aging population, coupled with high healthcare expenditure, further drives market growth. In March 2024, Leica Biosystems, a key player in the North American market, announced a strategic partnership with a leading artificial intelligence company to develop AI-powered IHC image analysis tools, aimed at improving diagnostic accuracy and efficiency.

Will Rising Prevalence Of Cancer Enhance Adoption of Immunohistochemistry (IHC) in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the Immunohistochemistry (IHC) market, driven by increasing healthcare expenditure, rising cancer incidence, and growing awareness of advanced diagnostic techniques. Countries like China, Japan, and India are at the forefront of this expansion, with significant investments in healthcare infrastructure and research capabilities. According to the National Health Commission of China, the country's healthcare spending reached 7.12 trillion yuan (approximately USD 1.1 Trillion) in 2023, representing a substantial increase from previous years. This investment is translating into improved access to advanced diagnostic tools, including IHC. In April 2024, Roche Diagnostics announced the opening of a new IHC reagent manufacturing facility in Shanghai, aiming to meet the growing regional demand and reduce delivery times for critical diagnostic products.

The rising prevalence of cancer in the Asia Pacific region is a key factor driving the adoption of IHC techniques. The Indian Council of Medical Research (ICMR) reported that new cancer cases in India are projected to increase by 12% by 2025, emphasizing the urgent need for accurate and efficient diagnostic methods. This trend is prompting healthcare providers across the region to invest in advanced IHC platforms and expand their diagnostic capabilities. The increasing focus on personalized medicine and targeted therapies is further fueling the demand for IHC-based biomarker testing. In March 2024, Danaher Corporation's Leica Biosystems division launched a new line of IHC antibodies specifically designed for prevalent cancer types in the Asia Pacific region, demonstrating the market's potential for tailored diagnostic solutions.

Competitive Landscape

The immunohistochemistry (IHC) market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the immunohistochemistry (IHC) market include:

• Agilent Technologies
• Roche Diagnostics
• Thermo Fisher Scientific
• Merck KGaA
• Abcam plc
• Bio-Rad Laboratories
• PerkinElmer, Inc.
• Dako (part of Agilent)
• Leica Biosystems
• Cell Signaling Technology
• Sigma-Aldrich (Merck)
• Miltenyi Biotec
• Genetex, Inc.
• Ventana Medical Systems (Roche)
• Fujifilm
• Biocare Medical
• Santa Cruz Biotechnology
• Zymed Laboratories (Thermo Fisher)
• NeoGenomics Laboratories
• Enzo Life Sciences

Latest Developments

• In September 2023, Thermo Fisher Scientific launched a new line of advanced antibodies specifically designed for immunohistochemistry applications, enhancing sensitivity and specificity in cancer diagnostics.
• In August 2023, Bio-Techne announced a collaboration with leading academic institutions to develop novel multiplex IHC techniques, enabling simultaneous detection of multiple biomarkers in tissue samples.

Immunohistochemistry (IHC) Market, By Category

• Product:
• Antibodies
• Reagents
• Equipment
• Application:
• Diagnostic
• Research
• Forensic
• End-User:
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antibodies
• 5.3 Reagents
• 5.4 Equipment
• 5.5 Kits

6 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Diagnostic
• 6.3 Research
• 6.4 Forensic

7 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY END USER

• 7.1 Overview
• 7.2 Hospitals & Diagnostic Laboratories
• 7.3 Academic & Research Institutes
• 7.4 Others

8 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 F. Agilent Technologies
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Roche Diagnostics
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Thermo Fisher Scientific
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Merck KGaA
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Abcam plc
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bio-Rad Laboratories
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 PerkinElmer, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Dako (part of Agilent)
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Leica Biosystems
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Cell Signaling Technology
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 F. Sigma-Aldrich (Merck)
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Miltenyi Biotec
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.13 Genetex, Inc.
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
  • 10.13.4 Key Developments
• 10.14 Ventana Medical Systems (Roche)
  • 10.14.1 Overview
  • 10.14.2 Financial Performance
  • 10.14.3 Product Outlook
  • 10.14.4 Key Developments
• 10.15 Fujifilm
  • 10.15.1 Overview
  • 10.15.2 Financial Performance
  • 10.15.3 Product Outlook
  • 10.15.4 Key Developments
• 10.16 Biocare Medical
  • 10.16.1 Overview
  • 10.16.2 Financial Performance
  • 10.16.3 Product Outlook
  • 10.16.4 Key Developments
• 10.17 Santa Cruz Biotechnology
  • 10.17.1 Overview
  • 10.17.2 Financial Performance
  • 10.17.3 Product Outlook
  • 10.17.4 Key Developments
• 10.18 Zymed Laboratories (Thermo Fisher)
  • 10.18.1 Overview
  • 10.18.2 Financial Performance
  • 10.18.3 Product Outlook
  • 10.18.4 Key Developments
• 10.19 NeoGenomics Laboratories
  • 10.19.1 Overview
  • 10.19.2 Financial Performance
  • 10.19.3 Product Outlook
  • 10.19.4 Key Developments
• 10.20 Enzo Life Sciences
  • 10.20.1 Overview
  • 10.20.2 Financial Performance
  • 10.20.3 Product Outlook
  • 10.20.4 Key Developments

11 Appendix

• 11.1 Related Research